Drugs / CD33 CAR T-cells
last change Jan 2025 re-read 3 minutes ago

CD33 CAR T-cells

Cell therapy targets CD33

Developed for
acute myeloid leukemia
Investigated by
Yake Biotechnology Ltd. · Zhejiang University

Trials 1

202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT06762132 Jan 2025 → Oct 2027 expected acute myeloid leukemia Zhejiang University Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD33 CAR T-cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT06762132 ↗
Modality Cell therapy “CD33 CAR-T Cell” NCT06762132 ↗
Route Intravenous “by intravenous infusion” NCT06762132 ↗
Target CD33 “targeting CD33 CAR-T Cell” NCT06762132 ↗